The 2023 DDR Landscape Review
- A review of 2023 focusing on H1 and H2 highlights, first clinic entries, a drug and trials breakdown by target and much more.
- A comprehensive analysis of DDR targets, developers and repair pathways, with a look at the Deals and Companies data by deal type, company location etc.
- An analysis of the top targets, diseases and biomarkers for both PARP and Non-PARP inhibitor trials, alongside the future of DDR, and key regulatory announcements.
About the report
The analysis is split into:
-
- A 2023 Landscape Review Summary – An analysis of overview of the key developments made within the DDR landscape during 2023, including highlights from H1 and H2 of 2023.
- Drug and Commercial Landscapes – Covers an analysis of the 580+ DDR-related drugs on Beacon with a focus on DDR targets, developers and repair pathways. In addition to a look at deals in the commercial space.
- Trial Landscape and Regulatory Updates – An analysis of the 1570+ clinical trials tracked on Beacon DDR and an overview of the commercial DDR landscape, highlighting the trends of deals and companies
You may also be interested in...
DDRi and ADC Combination Therapies Infographic
The 2024 DDR H1 Landscape Review
Investment Trends in Early-Stage Biopharma: A Beacon Data Perspective
Find out more
Beacon is the essential decision-support tool for developers of complex therapeutics. Our market-defining, proprietary ontologies, combined with the most accurate and comprehensive life sciences data, provide our customers with unparalleled visibility of the drug and trial landscape.
With Beacon, you can make drug development decisions with confidence. This is why 23 of the world’s top 25 drug developers trust us.
Speak with our team
Our dedicated account and research teams can help you with questions by showing you how this insight and data is collated on Beacon.
